Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

17.40USD
18 Oct 2017
Change (% chg)

-- (--)
Prev Close
$17.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
181,015
52-wk High
$20.40
52-wk Low
$8.40

Select another date:

Thu, Sep 14 2017

BRIEF-Epizyme announces pricing of public offering of common stock

* Epizyme announces pricing of public offering of common stock

BRIEF-Epizyme reports Q2 loss of $0.48/shr

* Epizyme reports second quarter 2017 financial results and clinical and business progress

BRIEF-US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

* US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

BRIEF-Epizyme announces Tazemetostat to be evaluated in NCI-COG pediatric MATCH trial

* Epizyme announces Tazemetostat to be evaluated in NCI’s recently initiated NCI-COG pediatric MATCH trial Source text for Eikon: Further company coverage:

BRIEF-Epizyme expands clinical collaboration with Genentech

* Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc

BRIEF-Epizyme announces tazemetostat granted orphan drug designation

* Epizyme announces tazemetostat granted orphan drug designation for the treatment of soft tissue sarcoma Source text for Eikon: Further company coverage:

BRIEF-Epizyme reports positive interim data from Phase 2 trial for tazemetostat

* Epizyme reports positive interim data from Phase 2 trial for tazemetostat in relapsed or refractory follicular lymphoma and dlbcl patients

BRIEF-Epizyme quarterly loss per share $0.56

* Quarterly loss per share $0.56 Source text: (http://bit.ly/2qgKGVs) Further company coverage:

BRIEF-Epizyme Earns $10 million milestone payment from Glaxosmithkline

* Epizyme earns $10 million milestone payment from glaxosmithkline for initiation of GLP Toxicology studies with novel methyltransferase inhibitor

BRIEF-Epizyme announces tazemetostat fast track designation for follicular lymphoma and plenary session on Phase 2 NHL data at ICML

* Epizyme announces tazemetostat fast track designation for follicular lymphoma and plenary session on Phase 2 NHL data at ICML

Select another date: